45153067 Non Small Cell Lung Cancer VINORELBINE the Tailored Treatment From Curative to Palliative...
-
Upload
ruki-hartawan -
Category
Documents
-
view
21 -
download
1
Transcript of 45153067 Non Small Cell Lung Cancer VINORELBINE the Tailored Treatment From Curative to Palliative...
7/18/2019 45153067 Non Small Cell Lung Cancer VINORELBINE the Tailored Treatment From Curative to Palliative Setting
http://slidepdf.com/reader/full/45153067-non-small-cell-lung-cancer-vinorelbine-the-tailored-treatment-from 1/51
NAVELBINEin
Non Small Cell Lung Cancer
VINORELBINEThe tailored treatment:
From Curative to Palliativesetting
Noorwati Sutandyo
Divisi Hematologi-Onkologi MedikDepartemen Ilmu Penyakit Dalam FKUI/
RSUPN Cipto Mangunkusumo/RSKD
7/18/2019 45153067 Non Small Cell Lung Cancer VINORELBINE the Tailored Treatment From Curative to Palliative Setting
http://slidepdf.com/reader/full/45153067-non-small-cell-lung-cancer-vinorelbine-the-tailored-treatment-from 2/51
Lung Cancer
Responsible for aboutone-third of all cancerdeaths
Accounts for moredeaths than breastcancer, prostate cancer,and colon cancerCOMBINED
80-90% of patients who
develop lung cancer willdie of the disease
80-85% NSCLCSchiller ASCO ‘00
7/18/2019 45153067 Non Small Cell Lung Cancer VINORELBINE the Tailored Treatment From Curative to Palliative Setting
http://slidepdf.com/reader/full/45153067-non-small-cell-lung-cancer-vinorelbine-the-tailored-treatment-from 3/51
Lung Cancer
• More than one-third cases in advanced
stageearly detection is difficult to do
• Dharmais National cancer Centre 64% instage IV
• No curative treatment for advanced
stage only systemic therapy
• Sytemic therapy: chemoteherapy and
targeted therapy
7/18/2019 45153067 Non Small Cell Lung Cancer VINORELBINE the Tailored Treatment From Curative to Palliative Setting
http://slidepdf.com/reader/full/45153067-non-small-cell-lung-cancer-vinorelbine-the-tailored-treatment-from 4/51
Kemoterapi
• Kemoterapi Pengobatan kanker dengan zat
atau obat yang berkhasiat membunuh sel kanker
• Obat disebut sitostatikapenghambat kerja sel
yang sedang tumbuh (proliferasi).
– sistemik (ke seluruh sistem tubuh)
– regional
7/18/2019 45153067 Non Small Cell Lung Cancer VINORELBINE the Tailored Treatment From Curative to Palliative Setting
http://slidepdf.com/reader/full/45153067-non-small-cell-lung-cancer-vinorelbine-the-tailored-treatment-from 5/51
Chemotherapy
• Mechanism is affected the DNA killedthe cell
Antimetabolites
DNA
DNA
transcription
DNA duplication
Mitosis
Alkylating agents
Spindle poisons
Intercalatingagents
7/18/2019 45153067 Non Small Cell Lung Cancer VINORELBINE the Tailored Treatment From Curative to Palliative Setting
http://slidepdf.com/reader/full/45153067-non-small-cell-lung-cancer-vinorelbine-the-tailored-treatment-from 6/51
Prinsip asar
• Mencegah sel kanker untuk bermultiplikasi,menginvasi, metastasis dan membunuhpenderitanya
• Mempengaruhi multiplikasi sel danpertumbuhan tumor, terutama sel yangpertumbuhannya cepat
• Pemberian yang efektif: efikasi maksimal
dengan efek samping seminimal mungkin
7/18/2019 45153067 Non Small Cell Lung Cancer VINORELBINE the Tailored Treatment From Curative to Palliative Setting
http://slidepdf.com/reader/full/45153067-non-small-cell-lung-cancer-vinorelbine-the-tailored-treatment-from 7/51
7/18/2019 45153067 Non Small Cell Lung Cancer VINORELBINE the Tailored Treatment From Curative to Palliative Setting
http://slidepdf.com/reader/full/45153067-non-small-cell-lung-cancer-vinorelbine-the-tailored-treatment-from 8/51
Principle Of Chemotherapy
7/18/2019 45153067 Non Small Cell Lung Cancer VINORELBINE the Tailored Treatment From Curative to Palliative Setting
http://slidepdf.com/reader/full/45153067-non-small-cell-lung-cancer-vinorelbine-the-tailored-treatment-from 9/51
Chemotherapy
• Chemoterapynot only kill
the cancer but also the
normal cell side effect
• But, the advantage ofchemotherapy relative
more cheaper than
targeted therapy
7/18/2019 45153067 Non Small Cell Lung Cancer VINORELBINE the Tailored Treatment From Curative to Palliative Setting
http://slidepdf.com/reader/full/45153067-non-small-cell-lung-cancer-vinorelbine-the-tailored-treatment-from 10/51
Efek Samping Kemoterapi
Mucositis
Nausea/vomiting
Diarrhea
Cystitis
Sterility
Myalgia
Neuropathy
Alopecia
Pulmonary fibrosis
Cardiotoxicity
Local reaction
Renal failure
Myelosuppression
Phlebitis
7/18/2019 45153067 Non Small Cell Lung Cancer VINORELBINE the Tailored Treatment From Curative to Palliative Setting
http://slidepdf.com/reader/full/45153067-non-small-cell-lung-cancer-vinorelbine-the-tailored-treatment-from 11/51
Targeted Therapy
7/18/2019 45153067 Non Small Cell Lung Cancer VINORELBINE the Tailored Treatment From Curative to Palliative Setting
http://slidepdf.com/reader/full/45153067-non-small-cell-lung-cancer-vinorelbine-the-tailored-treatment-from 12/51
• Targeted therapy affected the
transduction signal pathway related
associated with proliferation or survival
cancer cell no affected the normal
cell more tolerable side effect
• But, the price more expensive
Targeted Therapy
7/18/2019 45153067 Non Small Cell Lung Cancer VINORELBINE the Tailored Treatment From Curative to Palliative Setting
http://slidepdf.com/reader/full/45153067-non-small-cell-lung-cancer-vinorelbine-the-tailored-treatment-from 13/51
Regiment of Chemotherapy
• Cisplatin +vinorelbine
• Cisplatin+etoposide
• Cisplatin+vinblastin• Cisplatin+Gemcitabine
• Cisplatin+Docetaxel
• Carboplatin +Paclitaxel
7/18/2019 45153067 Non Small Cell Lung Cancer VINORELBINE the Tailored Treatment From Curative to Palliative Setting
http://slidepdf.com/reader/full/45153067-non-small-cell-lung-cancer-vinorelbine-the-tailored-treatment-from 14/51
Mekanisme Aksi Agen Sitotoksik pada Level
Siklus Sel
Antibiotics
S
(2-6h)G2
(2-32h)
M
(0.5-2h)
Alkylating agents
G1
(2- h)
G0
Vinca alkaloids
Mitotic inhibitors
Taxoids
Antimetabolites
7/18/2019 45153067 Non Small Cell Lung Cancer VINORELBINE the Tailored Treatment From Curative to Palliative Setting
http://slidepdf.com/reader/full/45153067-non-small-cell-lung-cancer-vinorelbine-the-tailored-treatment-from 15/51
Kemoterapi Kombinasi
Kemoterapi
kombinasi penting
utk mencapai logkill dimana
populasi sel tumor
tidak sensitif thd
obat tunggal
T j K t i
7/18/2019 45153067 Non Small Cell Lung Cancer VINORELBINE the Tailored Treatment From Curative to Palliative Setting
http://slidepdf.com/reader/full/45153067-non-small-cell-lung-cancer-vinorelbine-the-tailored-treatment-from 16/51
Tujuan Kemoterapi
Kombinasi
Meningkatkan Efikasi
Mekanisme kerja yang berbeda Efek Samping
Mekanisme resistensi yang berbeda
Aktivitas Keamanan
7/18/2019 45153067 Non Small Cell Lung Cancer VINORELBINE the Tailored Treatment From Curative to Palliative Setting
http://slidepdf.com/reader/full/45153067-non-small-cell-lung-cancer-vinorelbine-the-tailored-treatment-from 17/51
Pemilihan kombinasi regimen
• Perlu dipilih regimen paling tepat untukmemusnahkan kanker yang spesifik.
• Disebut regimen lini pertama/FIRST LINE
KEMOTERAPI• Kadangkala disebut DRUG of CHOICE/obat
terpilih.
• Proses ini memerlukan penelitian uji klinik yang
cermat dan diperlukan contoh yang banyak.• Regimen lini kedua bila regimen lini pertama,
tidak mempan
7/18/2019 45153067 Non Small Cell Lung Cancer VINORELBINE the Tailored Treatment From Curative to Palliative Setting
http://slidepdf.com/reader/full/45153067-non-small-cell-lung-cancer-vinorelbine-the-tailored-treatment-from 18/51
VINORELBINE
(Navelbine)
Inhibition of tubulin polymerization
with a differential affinity
Selective affinityfor mitotic spindle
microtubules
Weak affinityfor axonal
microtubules
Binet, Sem.Onc 1989
Lowneurotoxicity
Potentanti-tumoral activity
T t t f NSCLC
7/18/2019 45153067 Non Small Cell Lung Cancer VINORELBINE the Tailored Treatment From Curative to Palliative Setting
http://slidepdf.com/reader/full/45153067-non-small-cell-lung-cancer-vinorelbine-the-tailored-treatment-from 19/51
CT+RT
combination
Treatment adapted to each stage of the disease
Treatments of NSCLC:
A strategy adapted to each case
Resectabledisease
I, II, IIIA
Unresectabledisease
IIIB
Unresectabledisease
IV
Adjuvant CTPre-operative CT
Palliative CT
Platinum-based or
Platinum-free regimens
ANITA Adj t NAVELBINE® + CDDP Ob ti
7/18/2019 45153067 Non Small Cell Lung Cancer VINORELBINE the Tailored Treatment From Curative to Palliative Setting
http://slidepdf.com/reader/full/45153067-non-small-cell-lung-cancer-vinorelbine-the-tailored-treatment-from 20/51
ANITA: Adjuvant NAVELBINE ® + CDDP vs Observation
Long-term survival benefit: 8.4% at 7 years
13ANITA
Overall survivalOverall survival -- ITT populationITT population
months
S u r v i v a l D i s t r i b u t i o n F u n c t i o n
1.00
0.75
0.50
0.25
0
0 20 40 60 80 100 120
ObsObs
NVB + CDDPNVB + CDDP
Douillard, Lancet Oncology 2006
Completely resected
stage Ib to IIIA patientsObservation
n= 433
NAVELBINE 30 mg/m²/w
CDDP 100 mg/m² D1
q 4 weeks - 4 cycles
n= 407 MS (m) 43.7 65.7
2-year survival
5-year survival
7-year survival
+4.7%
+8.6%
+8.4%
p= 0.017
Efficacy in randomized platin based adjuvant trials
7/18/2019 45153067 Non Small Cell Lung Cancer VINORELBINE the Tailored Treatment From Curative to Palliative Setting
http://slidepdf.com/reader/full/45153067-non-small-cell-lung-cancer-vinorelbine-the-tailored-treatment-from 21/51
Trial Median
Survival
5-Year
Survival
Hazard
Ratio
ALPIMVP vs control
55.2 m48 m
p = 0.585
----
HR: 0.9695% CI:
[ 0.81 – 1.13]
IALT
P-based vs con trol
50.8 m
44.4 m p = 0.03
44.5%
40.4%
HR: 0.86
95% CI:
[ 0.76 - 0.98]
JBR10
NP vs c ontro l 94 m73 m p = 0.04
69%54%
HR: 0.69
95% CI:[ 0.52 - 0.91]
CALGB 9633
PC vs control
95 m
78 m p= 0.37
59%
57%
HR: 0.8095% CI:
[ 0.60 – 1.07]
ANITA
NP vs co ntrol
65.7 m
43.7m p = 0.017
51.2%
42.6%
HR: 0.80
95% CI:[ 0.66 - 0.96]
Efficacy in randomized platin-based adjuvant trials
3/5 adjuvant trials showed significant survival improvementwith chemotherapy
+ 4%
+ 15%
+ 8%
7/18/2019 45153067 Non Small Cell Lung Cancer VINORELBINE the Tailored Treatment From Curative to Palliative Setting
http://slidepdf.com/reader/full/45153067-non-small-cell-lung-cancer-vinorelbine-the-tailored-treatment-from 22/51
LACE
meta-analysis
LACE NAVELBINE
meta-analysis
Population Patients with completely resected NSCLC
Inclusion criteria CDDP-based vs Obs
CDDP-based + PORT vs PORT
NVB+CDDP vs Obs
NVB+CDDP + PORT vs PORT
Included studies 5 studies included
ALPI, BLT, IALT, JBR10, ANITA
4 studies included
BLT, IALT, JBR10, ANITA
Pts
characteristics
N = 4584
IA: 8%, IB: 30%, II: 35%, III: 27%
N = 1888
IA: 2%, IB: 34%, II: 38%, III: 26%
Main objective Overall Survival of
CDDP-based regimens
Overall Survival of
NVB+CDDP regimens
PORT= post-operative RT Pignon, ASCO 2006, Douillard, ESMO 2006
Lung Adjuvant Cisplatin Evaluation (LACE)
Contribution of NAVELBINE® in the adjuvant setting
7/18/2019 45153067 Non Small Cell Lung Cancer VINORELBINE the Tailored Treatment From Curative to Palliative Setting
http://slidepdf.com/reader/full/45153067-non-small-cell-lung-cancer-vinorelbine-the-tailored-treatment-from 23/51
Contribution of NAVELBINE ® in the adjuvant setting
NAVELBINE + cisplatin
Control
+8.9%
p=0.0007p=0.004
55
46.1
Time (years)
S u r v i v a l ( % )
0 1 2 3 4 5 ≥6
100
80
60
40
20
0
Chemotherapy
Control
61.0
57.148.8
43.5
Time (years)
S u r v i v a l ( % )
0 1 2 3 4 5 ≥6
1.0
80
60
40
20
0
+5.3%
LACE LACE NAVELBINE ®
• 5 trials• Absolute survival benefit of 5.3% at 5-years
Pignon, ASCO 2006
• 4 trials• Absolute survival benefit of 8.9% at 5-years
Douillard, ESMO 2006- ICACT 2007
NAVELBINE ® + Cisplatin is the new standard of care
as adjuvant treatment for NSCLC
Adjuvant NAVELBINE+CDDP:
7/18/2019 45153067 Non Small Cell Lung Cancer VINORELBINE the Tailored Treatment From Curative to Palliative Setting
http://slidepdf.com/reader/full/45153067-non-small-cell-lung-cancer-vinorelbine-the-tailored-treatment-from 24/51
Adjuvant NAVELBINE+CDDP:a new standard of care
Mediansurvival
(p < 0.03)Observation 44.4 m
CT (27% NVB+CDDP) 50.8 m
IALT, NEJM 2004
n=1867 (Stages I: 36%, II: 25%, III: 39% )
(p = 0.009)
JBR10, NEJM 2005n=482 (Stages IB: 45%, II: 55%)
Mediansurvival
Observation 73 m
NVB+CDDP 94 m
Observation 43.7 mNVB+CDDP 65.7 m
ANITA, ASCO 2005n=840 (Stages I: 35%, II: 30%, IIIA : 35% )
Mediansurvival
(p = 0.01)
With 3 positive trials, NVB+CDDP has the largest experienceas adjuvant chemotherapy
NAVELBINE + CDDP
7/18/2019 45153067 Non Small Cell Lung Cancer VINORELBINE the Tailored Treatment From Curative to Palliative Setting
http://slidepdf.com/reader/full/45153067-non-small-cell-lung-cancer-vinorelbine-the-tailored-treatment-from 25/51
Spasova, Neoplasma 02
NVB-CDDP yields high resection rates
NAVELBINE + CDDPas preoperative CT for stage III NSCLC
Phase II studyn= 56
IIIA 36%, IIIB 64%
NAVELBINE D1, D8 30 mg/m²
CISPLATIN D1 80 mg/m²
every 3 weeks
OR
Resection rate
Complete resection
MS
1-YS
2-YS
54%
77%
32% (27% T4 – 50% N3)
21.5 m
89% (Compl. Res.) vs 45% (Incompl. Res.)
61% (Compl. Res.) vs 10% (Incompl. Res.)
NAVELBINE + IFO + CDDP
7/18/2019 45153067 Non Small Cell Lung Cancer VINORELBINE the Tailored Treatment From Curative to Palliative Setting
http://slidepdf.com/reader/full/45153067-non-small-cell-lung-cancer-vinorelbine-the-tailored-treatment-from 26/51
Gottfried, WCLC 2005
Effective triplet CT in patients with large LA NSCLC
NAVELBINE + IFO + CDDPas preoperative CT
Phase III studyn= 155
IIB 27%, IIIA 65%, IIIB
8%
NAVELBINE D1, D5 25 mg/m²
IFOSFAMIDE D1 3000 mg/m²
CISPLATIN D1 80 mg/m²
every 3 weeks
OR
Resection rate
Complete resection
Time to surgery
58.7%
69%
74% (79/107 pts)
32 days
Treatments of NSCLC
7/18/2019 45153067 Non Small Cell Lung Cancer VINORELBINE the Tailored Treatment From Curative to Palliative Setting
http://slidepdf.com/reader/full/45153067-non-small-cell-lung-cancer-vinorelbine-the-tailored-treatment-from 27/51
CT+RT
combination
Treatment adapted to each stage of the disease
Treatments of NSCLC
Resectabledisease
I, II, IIIA
Unresectabledisease
IIIB
Unresectabledisease
IV
Adjuvant CT
Pre-operative CT
Palliative CT
Platinum-based or
Platinum-free regimens
Unresectable stage III patients :
7/18/2019 45153067 Non Small Cell Lung Cancer VINORELBINE the Tailored Treatment From Curative to Palliative Setting
http://slidepdf.com/reader/full/45153067-non-small-cell-lung-cancer-vinorelbine-the-tailored-treatment-from 28/51
Unresectable stage III patients :ASCO Guidelines for CT+RT
CT plus RT prolongs survival compared to RT alone
CT may best be started soon after the diagnosis ofunresectable NSCLC has been made
Delaying CT may negate the survival benefits of treatment
The duration of CT should be 2 to 4 cycles of initial
platinum-based CT(Pfister, JCO 04)
NAVELBINE ® + CDDP:S ti l CT d RT t CT+RT+ lid ti ?
7/18/2019 45153067 Non Small Cell Lung Cancer VINORELBINE the Tailored Treatment From Curative to Palliative Setting
http://slidepdf.com/reader/full/45153067-non-small-cell-lung-cancer-vinorelbine-the-tailored-treatment-from 29/51
Sequential CT and RT or concurrent CT+RT+ consolidation?
Randomised study
Concurrent NVB+CDDP and radiotherapy appears more efficacious
than sequential use of the same therapeutics…
n=102 IIIA 15%
IIIB 85%
NVB +CDDP
then RT (60 Gy)
NVB+CDDP + RT (60 Gy)
then NVB+CDDP
OR 47% 80%
CR 17% 21%
Median Survival 12.9 m 16.6 m
1-YS 53% 69%
2-YS 14% 34%Zatloukal, Lung Cancer 2004
NAVELBINE ® + CDDP:Sequential CT and RT or concurrent CT+RT+ consolidation?
7/18/2019 45153067 Non Small Cell Lung Cancer VINORELBINE the Tailored Treatment From Curative to Palliative Setting
http://slidepdf.com/reader/full/45153067-non-small-cell-lung-cancer-vinorelbine-the-tailored-treatment-from 30/51
But concurrent approach requires patient’s selection
to limit toxicity burdens
Phase III study
Gr 3-4, % pts
NVB +CDDP
then RT (60 Gy)
NVB+CDDP + RT
then NVB+CDDP
Neutropenia
Febrile neutropenia
Thrombocytopenia
Esophagitis
Nausea/Vomiting
Neurotoxicity
Pulmonary toxicity
40%
2%
4%
4%
15%
2%
2%
65%
8%
6%
18%
39%
4%
4%
Sequential CT and RT or concurrent CT+RT+ consolidation?
Zatloukal, Lung Cancer 2004
Treatments of NSCLC
7/18/2019 45153067 Non Small Cell Lung Cancer VINORELBINE the Tailored Treatment From Curative to Palliative Setting
http://slidepdf.com/reader/full/45153067-non-small-cell-lung-cancer-vinorelbine-the-tailored-treatment-from 31/51
CT+RT
combination
Treatment adapted to each stage of the disease
Treatments of NSCLC
Resectabledisease
I, II, IIIA
Unresectabledisease
IIIB
Unresectabledisease
IV
Adjuvant CT
Pre-operative CT
Palliative CT
Platinum-based or
Platinum-free regimens
1st line NAVELBINE D1,D8 + CDDP versus
7/18/2019 45153067 Non Small Cell Lung Cancer VINORELBINE the Tailored Treatment From Curative to Palliative Setting
http://slidepdf.com/reader/full/45153067-non-small-cell-lung-cancer-vinorelbine-the-tailored-treatment-from 32/51
Major efficacy and significantly lower cost for NAVELBINE+CDDP
1st line NAVELBINE D1,D8 + CDDP versus
GEM+CDDP
Phase III study
n=272
1st line: NVB+CDDP q3w*
2nd line: GEM weekly
1st line: GEM+CDDP q3w*
2nd line: NVB weekly
Efficacy
OR 1st Line
MS
32.1%
11m
26.7%
11m
Toxicity (Gr 3-4, %pts)Neutropenia
Thrombopenia
30.7%
0%
17.7%
9.3%
Cost
Total direct costs
per patient
882 € 2,900 €
Martoni, Eur. J. Cancer 2005
(p= 0.004)
(p< 0.0001)
(p= 0.017)
*Followed by maintenance of the same drug NVB or GEM as in a single agentfor responding and stable disease patients
Efficacy of third generation
7/18/2019 45153067 Non Small Cell Lung Cancer VINORELBINE the Tailored Treatment From Curative to Palliative Setting
http://slidepdf.com/reader/full/45153067-non-small-cell-lung-cancer-vinorelbine-the-tailored-treatment-from 33/51
NVB D1,D8 +CDDP:of the most active combinations in 1st line NSCLC
Efficacy of third generationCDDP-based chemotherapies
Phase III studies OR MS 1-YS Nb
studies
NVB weekly+CDDP
q4w25-36% 8.8-10.3m 33.-42% 7
NVB D1,D8+CDDPq3w
27-39% 9.6-11m 39-41% 4
GEM+CDDPq3-4 w
22-42% 8.1-11m 32-44% 8
PTX+CDDPq3w
21-41% 7.8-10m 31-43% 5
DCT+CDDPq3w
17-37% 7.4-11.4m 31-48% 4
NAVELBINE+Carboplatin
7/18/2019 45153067 Non Small Cell Lung Cancer VINORELBINE the Tailored Treatment From Curative to Palliative Setting
http://slidepdf.com/reader/full/45153067-non-small-cell-lung-cancer-vinorelbine-the-tailored-treatment-from 34/51
Clinical benefit response in one third of the patients
NAVELBINE Carboplatin
Phase III study
vs NVB+GEM
n=316
NVB 30 mg/m² D1,D8
CBDCA AUC 5 D1
every 3 weeks
OR (ITT)
Disease controlMS
1-YS
20.8%
66%8.6 m
34.4%
Tan, Lung Cancer 2005
NAVELBINE + CBDCA
7/18/2019 45153067 Non Small Cell Lung Cancer VINORELBINE the Tailored Treatment From Curative to Palliative Setting
http://slidepdf.com/reader/full/45153067-non-small-cell-lung-cancer-vinorelbine-the-tailored-treatment-from 35/51
Tolerance %pts
Neutropenia Gr 3-4
Febrile neutropenia
Nausea/Vomiting Gr 3
Constipation Gr 3
44.5%
11%
4%
4%
Tolerance profile suitable for an outpatient treatment
(Tan, Lung Cancer 2005)
NAVELBINE CBDCA
Studies with NAVELBINE+Carboplatin (n>50)
7/18/2019 45153067 Non Small Cell Lung Cancer VINORELBINE the Tailored Treatment From Curative to Palliative Setting
http://slidepdf.com/reader/full/45153067-non-small-cell-lung-cancer-vinorelbine-the-tailored-treatment-from 36/51
NVB+CBDCA: the efficacy of a standard CDDP-based regimen
with the convenience of CBDCA
p ( )
NAVELBINE + CBDCA n MS
Tan, Lung Cancer 2005
Maguire, WCLC 2003
Bretti, Onco. Rep. 2001Santomaggio, Am. JCO 1998
Cremonesi, Oncol. 2003
Parente, EJC 1997
158
150
83
77
52
75
8.5 m
8.6 m
9 m
9.5 m
12.3 m
8 m
n= 595 MS= 8-12.3 m
Efficacy of third generation
7/18/2019 45153067 Non Small Cell Lung Cancer VINORELBINE the Tailored Treatment From Curative to Palliative Setting
http://slidepdf.com/reader/full/45153067-non-small-cell-lung-cancer-vinorelbine-the-tailored-treatment-from 37/51
NVB+CBDCA:An effective outpatient chemotherapy
y gCBDCA-based chemotherapies
Phase II and III studies OR MS 1-YS Nb
studies
NVB+CBDCA 21-45% 8-12.3m 34% 6*
GEM+CBDCA 29-42% 7.6-11m 32-44%6
PTX+CBDCA 10-46% 8.1-11m 34-44% 7
DCT+CBDCA 24.5-34% 7.8-9.6m 38-39% 3
(*1 phase III)
Quality of life of NAVELBINE + CDDP/CBDCA
7/18/2019 45153067 Non Small Cell Lung Cancer VINORELBINE the Tailored Treatment From Curative to Palliative Setting
http://slidepdf.com/reader/full/45153067-non-small-cell-lung-cancer-vinorelbine-the-tailored-treatment-from 38/51
0
25
50
y
NAVELBINE + CDDP/CBDCA= Improved quality of life
Tan, Lung Cancer 2005
0
25
50
37%
% pts
Kelly, JCO 2001
Quality of life improvement
32%
NAVELBINE + CDDP(n=202)
Clinical benefit response
NAVELBINE + CBDCA(n=111)
% pts
NAVELBINE in platinum-based combinations
7/18/2019 45153067 Non Small Cell Lung Cancer VINORELBINE the Tailored Treatment From Curative to Palliative Setting
http://slidepdf.com/reader/full/45153067-non-small-cell-lung-cancer-vinorelbine-the-tailored-treatment-from 39/51
Recommended doses
NAVELBINE 30mg/m² D1,D8
CDDP 80mg/m² D1
3-week cycles
NAVELBINE 25-30mg/m² D1,D8CBDCA AUC 5 D1
3-week cycles
Elderly and Lung Cancer
7/18/2019 45153067 Non Small Cell Lung Cancer VINORELBINE the Tailored Treatment From Curative to Palliative Setting
http://slidepdf.com/reader/full/45153067-non-small-cell-lung-cancer-vinorelbine-the-tailored-treatment-from 40/51
Elderly and Lung Cancer
• In Dharmais Hospital 2007elderly
Age (years old) Male Female
<20 0 0
20-40 5 2
40-60 29 10
>60 27 1261 (71%) 24 (29%)
39/85
46%
Elderly patients:A l ti ith ifi i t
7/18/2019 45153067 Non Small Cell Lung Cancer VINORELBINE the Tailored Treatment From Curative to Palliative Setting
http://slidepdf.com/reader/full/45153067-non-small-cell-lung-cancer-vinorelbine-the-tailored-treatment-from 41/51
A population with specific requirements
Treatment must be adapted to each patient’s profile
Level of independence Therapeutic options
No need of rehabilitation:- complete functional independence (ADL, IADL)
- negligible co-morbidity
Poly CT can be feasible
Reversible with rehabilitation:- dependence in ADL
- function limiting co-morbidity
Mono CT should be preferred
Irreversible:- dependence in ADL
- severe co-morbidity
BSC is the best option
Adapted from Balducci, Management of Cancer in the older person: a practical approach; The Oncologist 2000
NAVELBINE single agent in elderly patients
7/18/2019 45153067 Non Small Cell Lung Cancer VINORELBINE the Tailored Treatment From Curative to Palliative Setting
http://slidepdf.com/reader/full/45153067-non-small-cell-lung-cancer-vinorelbine-the-tailored-treatment-from 42/51
n= 154
median age= 74
73% stage IV
NVB 30 mg/m2
D1, D8
every 3 weeks
BSC
OR
Disease control
Median Survival
1-YS
20%
50%
6.5 m
32%
-
-
4.8 m
14%
Gridelli, JNCI 99
NAVELBINE improves Survival vs BSC
ELVIS Phase III study
p = 0.03
NAVELBINE single agent in elderly patients
7/18/2019 45153067 Non Small Cell Lung Cancer VINORELBINE the Tailored Treatment From Curative to Palliative Setting
http://slidepdf.com/reader/full/45153067-non-small-cell-lung-cancer-vinorelbine-the-tailored-treatment-from 43/51
Gridelli, JNCI 1999
ELVIS Phase III study
WHO G3/4, % pts
NVB 30 mg/m2 D1, D8every 3 weeks
Neutropenia
Infection
VomitingCardiac toxicity
Constipation
Alopecia
4% Gr 4
none
1 pt1 pt Gr 2
5.6%
4% Gr 3
NAVELBINE single agent in elderly patients
7/18/2019 45153067 Non Small Cell Lung Cancer VINORELBINE the Tailored Treatment From Curative to Palliative Setting
http://slidepdf.com/reader/full/45153067-non-small-cell-lung-cancer-vinorelbine-the-tailored-treatment-from 44/51
Gridelli, JNCI 99
NAVELBINE improves Quality of Life
ELVIS Phase III study
NVB 30 mg/m2
D1, D8 versus BSC
q3 weeks
EORTC - C30 scales
EORTC - LC13 modules
Significant improvement with NVB for:
cognitive function – pain
dyspnea - pain in shoulder - pain medication
NAVELBINE single agent in elderly patients
7/18/2019 45153067 Non Small Cell Lung Cancer VINORELBINE the Tailored Treatment From Curative to Palliative Setting
http://slidepdf.com/reader/full/45153067-non-small-cell-lung-cancer-vinorelbine-the-tailored-treatment-from 45/51
Gridelli,JNCI 03
NAVELBINE is the standard for elderly patients
MILES Phase III study
median age= 74
70% stage IV
PS 2= 19%
NVB30 mg/m²
D1, D8 q3w(n = 233)
GEM(n = 233)
NVB + GEM(n = 232)
OR 18% 16% 21%
MS 8.3 m 6.5 m 6.9 m
1-YS 38% 28% 30%
NAVELBINE + CDDP in the Elderly
7/18/2019 45153067 Non Small Cell Lung Cancer VINORELBINE the Tailored Treatment From Curative to Palliative Setting
http://slidepdf.com/reader/full/45153067-non-small-cell-lung-cancer-vinorelbine-the-tailored-treatment-from 46/51
PolyCT NVB+CDDP is effective and feasible for fit elderly patients
Phase II study
n= 33
St IIIA, IIIB, IV
Median age= 73
NAVELBINE D1, D8, D15 30 mg/m²
CISPLATIN D1, D8, D15 25 mg/m²
q4 weeks
OR
Disease control
Median duration response
MS
Cinical benefit
Neutropenia Gr 3-4
48%
77%
7 m
11 m
46% responders
44.5% pts including 1 toxic death
(PS2 / infection)Mattioli, ESMO 02
NAVELBINE + CBDCA in the Elderly
7/18/2019 45153067 Non Small Cell Lung Cancer VINORELBINE the Tailored Treatment From Curative to Palliative Setting
http://slidepdf.com/reader/full/45153067-non-small-cell-lung-cancer-vinorelbine-the-tailored-treatment-from 47/51
The efficacy and convenience of NVB+CBDCA for fit elderly patients
Phase II study
n= 72
St IV Median age= 75
NAVELBINE 25 mg/m² D1, D8
CBDCA AUC 5 D1q3 weeks
OR
Disease control
PFS
MS
Neutropenia Gr 3-4
Febrile neutropenia
Thrombocytopenia Gr 3-4
Fatigue
Neurotoxicity
31%
67%
6.7 m
8.8 m
28%
4%
8%
None
3%Depperman, ESMO 2004
NAVELBINE in the Elderly
R d d d
7/18/2019 45153067 Non Small Cell Lung Cancer VINORELBINE the Tailored Treatment From Curative to Palliative Setting
http://slidepdf.com/reader/full/45153067-non-small-cell-lung-cancer-vinorelbine-the-tailored-treatment-from 48/51
Recommended dose
NAVELBINE 30mg/m² D1,D8
3-week cycles
From curative to palliative settings
7/18/2019 45153067 Non Small Cell Lung Cancer VINORELBINE the Tailored Treatment From Curative to Palliative Setting
http://slidepdf.com/reader/full/45153067-non-small-cell-lung-cancer-vinorelbine-the-tailored-treatment-from 49/51
NAVELBINE: a reference treatment for NSCLC
Unresectable
diseaseIV
Unresectable
diseaseIIIB
Resectable
diseaseI, II, IIIA
NVB+CDDP
Adjuvant or
Pre-operative CT
NVB+CDDP+RT
Sequential and
concomitant
NVB+CDDP
NVB+CBDCA
NVB single agent
Palliative CT
NAVELBINE in practice
7/18/2019 45153067 Non Small Cell Lung Cancer VINORELBINE the Tailored Treatment From Curative to Palliative Setting
http://slidepdf.com/reader/full/45153067-non-small-cell-lung-cancer-vinorelbine-the-tailored-treatment-from 50/51
Perform blood count before any administration
Short infusion (NAVELBINE diluted in 50-100 cc saline solution, 10’ infusion)
NAVELBINE should be administered as the first cytotoxic given in a combination
As a single-agent:
30 mg/m²/w
In combination:
25-30 mg/m² D1, D8 every 3 weeks
NAVELBINE: a reference treatment for NSCLC
7/18/2019 45153067 Non Small Cell Lung Cancer VINORELBINE the Tailored Treatment From Curative to Palliative Setting
http://slidepdf.com/reader/full/45153067-non-small-cell-lung-cancer-vinorelbine-the-tailored-treatment-from 51/51